GLP-1s to Enhance Lasting Optimal Weight
NCT06861439 on ClinicalTrials.gov · last registry update 2026-10-02
Closed to new participants; the 40 already enrolled are still being followed. Due to report 30 October 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in total body lean mass. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P4
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- Wake Forest University Health Sciences
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2025-07-07
- Primary completion
- 2027-10-30 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-02 | Reporting date moved | 2026-10-30 → 2027-10-30 12 months later |
| 2026-09-28 | Reporting date moved | 2026-09-30 → 2026-10-30 1 months later |
Primary outcome
Change in total body lean mass
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.